Learn about the PREDICT clinical trial for Dry Eye Disease

DED is a multifactorial disease affecting >110M people worldwide1 in which ocular surface inflammation plays a central role in sustaining the pathological state2.

The DED patient population is heterogenous with various clinical features, often overlapping with one another. With currently available treatment options, eye care practitioners often need to adapt their treatment strategies and rely on ‘trial and error’ to find the best approach for each patient.

Oculis is developing Licaminlimab, an innovative anti-TNFα eye drop candidate with dual mechanism of action, anti-inflammatory and anti-apoptosis, to help address some of the remaining unmet medical needs with a precision medicine approach.

PREDICT is a registrational trial leveraging a genotype-based approach to investigate Licaminlimab for the treatment of dry eye disease. This trial is anticipated to start in Q4 2025.

Together, we can help advance treatment options for DED.

Licaminlimab is an investigational product and has not received regulatory approval for commercial use in any country. Safety and efficacy of Licaminlimab for dry eye disease have not been established.

References:

1. Jain H, et al. (2020): Dry eye disease landscape and forecast. Decision Resources Group (DRG). Prevalence for G7 countries: France, Germany, Italy, Japan, Spain, UK, and US. 2. Bron AJ et al. (2017) TFOS DEWS II pathophysiology report. The Ocular Surface; vol. 15 issue 3: 438-510.